Chapter Four

Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 13, 2024
Biotechnology, Pharmaceutical, Health, Directory, Chapter Three, Chapter Four, Chapter, Chapter One, Confidentiality, Intellectual property, Orientation, Chapter Five, Music

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

Key Points: 
  • Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
  • This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors.
  • The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
  • Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Biotechnology Collaboration Agreements Analysis Report 2024: Global Coverage, Deal Financials, Contract Documents, Deal Trends, Leading Dealmakers, Comprehensive Deal Directory 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 13, 2024
Biotechnology, Other Professional Services, Professional Services, Health, Directory, Chapter Three, Chapter Four, Chapter, Chapter One, Confidentiality, A-Z, Orientation, Chapter Five, Chapter Six, Lease

Collaboration Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter collaboration deals.

Key Points: 
  • Collaboration Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter collaboration deals.
  • Fully revised and updated, the report provides details of collaboration deals from 2019 to 2024.
  • The report provides access to collaboration deal payment terms as announced between the parties.
  • Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.

Pharmaceuticals and Biotechnology Asset Purchase Deal Trends Analysis Report and Directory 2024: Benchmark Data for Deals Signed Since 2016 by the World's Leading Life Science Companies - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 13, 2024
Biotechnology, Pharmaceutical, Health, Directory, Chapter Three, Chapter Four, Chapter, Chapter One, Confidentiality, A-Z, Orientation, Chapter Five, Chapter Six

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

Key Points: 
  • Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
  • The report provides access to asset purchase deal payment terms as announced between the parties.
  • The report focuses on four primary types of asset available for purchase, business assets, product assets, royalty assets, and technology assets.
  • The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016.

Complementary cost-benefit assessment on the Integrated Reporting Framework - Closer alignment with FINREP solo

Retrieved on: 
星期五, 四月 5, 2024
Reproduction, The, European Banking Authority, Level, Exercise, Integration, Frankfurt, OJ, Sale, Council, Prudential, BIRD, PDF, ITS, ECB, Chapter Three, International, ESCB, CRR, Feasibility study, Data collection, A5, Collection, Financial instrument, Person, A4, EBA, Content, Part, Classification, Chapter Four, Commission, CBA, Publication, Chapter Five, Chapter Six, Fair value, European Central Bank, NCBS, Central bank, Chapter Two, European Parliament, Analysis, Capital Requirements Regulation 2013, Data, BAD, AnaCredit, Risk management

Complementary cost-benefit assessment on the Integrated Reporting Framework ?

Key Points: 
    • Complementary cost-benefit assessment on the Integrated Reporting Framework ?
      Executive summary

      2

      towards closer alignment of the two frameworks, rather than implementing all
      changes at once.

    • Complementary cost-benefit assessment on the Integrated Reporting Framework ?
      Executive summary

      3

      1

      Introduction
      The complementary IReF cost-benefit assessment (CBA) followed an earlier
      consultation on an initial CBA that was launched in 2020.

    • The report summarises the feedback received from the banking industry on the
      possible closer alignment of the IReF with FINREP solo.
    • Complementary cost-benefit assessment on the Integrated Reporting Framework ?
      Introduction

      4

      2

      General question on closer alignment
      with FINREP solo
      Closer alignment between the IReF and FINREP solo could allow more substantial
      use of the IReF dataset for supervisory purposes, with the potential benefit of
      reducing ad hoc requests to reporting agents due to a more analytical and stable
      dataset.

    • The ECB legal framework for collecting FINREP solo information (Regulation (EU)
      2015/34)4 currently sets up four different levels of reporting for proportionality
      measures:
      ?

      FINREP data points;

      ?

      over-simplified FINREP;

      ?

      simplified FINREP;

      ?

      full FINREP.

    • Closer alignment does not mean that data
      under the IReF will be collected from reporting agents at the level of the legal entity
      in its entirety.
    • Complementary cost-benefit assessment on the Integrated Reporting Framework ? General
      question on closer alignment with FINREP solo

      5

      Chart 2.1
      General assessment on closer alignment between the IReF and FINREP solo

      Notes: The percentages are calculated for each driver as the simple average of the corresponding frequencies across euro area
      countries.

    • See Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of
      the IReF Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results
      are calculated.
    • Members also raised the point that IReF
      information required for closer alignment with FINREP solo would only be collected
      from institutions that are currently subject to FINREP solo reporting.
    • The open text comments that were received in the complementary CBA show that
      different approaches to reporting at the level of the reporting agent may result in
      different expectations regarding closer alignment.
    • There
      were also several comments regarding the frequency and timeliness of the reporting
      of attributes needed for closer alignment with FINREP.
    • Many comments questioned which accounting standards will underpin IReF
      reporting, as those applicable to statistical reporting are often different from those
      relating to FINREP solo reporting.
    • Complementary cost-benefit assessment on the Integrated Reporting Framework ? General
      question on closer alignment with FINREP solo

      7

      3

      Extensions related to concepts already
      available in the IReF baseline scenario
      The IReF baseline scenario includes several accounting concepts that only apply to
      specific financial instruments.

    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • See
      Annex B of the report ?Complementary cost-benefit assessment of the Integrated Reporting Framework ? Extension of the IReF
      Regulation to cover country-specific requirements? published on the ECB?s website for information on how national results are
      calculated.
    • Complementary cost-benefit assessment on the Integrated Reporting Framework ? Annex A
      Results by type and size of respondent

      57

      ? European Central Bank, 2024
      Postal address
      Telephone
      Website

      60640 Frankfurt am Main, Germany
      +49 69 1344 0
      www.ecb.europa.eu

      All rights reserved.

Distribution in Pharmaceuticals and Biotechnology Partnering Deal Trends Report 2024: Analysis of Agreements Signed Since 2016 Featuring Over 1,500 Companies - ResearchAndMarkets.com

Retrieved on: 
星期五, 三月 8, 2024
Biotechnology, Pharmaceutical, Health, Chapter Three, A-Z, Chapter Five, Chapter One, Directory, Confidentiality, Orientation, Chapter, Chapter Six, Chapter Four, Lease

The "Distribution Deals in Pharmaceuticals and Biotechnology 2016 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Distribution Deals in Pharmaceuticals and Biotechnology 2016 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals with details of distribution deals from 2016 to 2024.
  • The report provides access to distribution deal payment terms as announced between the parties.
  • Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

Global Long Duration Energy Storage Industry Report 2023-2044: Materials, Equipment Markets, Technology Roadmaps, Manufacturers, Winners, Losers, Alternatives - ResearchAndMarkets.com

Retrieved on: 
星期三, 二月 28, 2024
Technology, Manufacturing, Batteries, Other Energy, Utilities, Other Manufacturing, Alternative Energy, Energy, Engineering, Hardware, Chemicals, Plastics, Hydrogen, Gravity battery, CAES, Ammonia, Growth, Methane, SWOT, RFB, Alternatives, B cell, Highview Power, Comment, Chapter Four

The "Long Duration Energy Storage LDES Reality: Materials, Equipment Markets in 35 Lines, Technology Roadmaps, Manufacturers, Winners, Losers, Alternatives" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Long Duration Energy Storage LDES Reality: Materials, Equipment Markets in 35 Lines, Technology Roadmaps, Manufacturers, Winners, Losers, Alternatives" report has been added to ResearchAndMarkets.com's offering.
  • The Long Duration Energy Storage (LDES) report provides in-depth look at the future landscape of the industry – from materials and equipment markets to technology roadmaps, and company profiles.
  • The report delves into the reality of LDES, revealing potential winners and losers and exploring a wide array of alternatives through analytical forecasts stretching from 2024 to 2044.
  • Similar in-depth analysis is provided for other storage technologies like Compressed Air Energy Storage (CAES), Chemical Intermediary LDES (hydrogen, ammonia, methane), and Pumped Hydro Storage.

EudraVigilance - EVWEB user manual

Retrieved on: 
星期日, 三月 10, 2024
International Organization (journal), Level 2, Automation, Chapter Two, ACK, ISO, Classification, SSL, Sender, Clinical trial, Radio, Immediate, European, CAPS, European Medicines Agency, Report, MDN, ICH, Medicine, HTML, Internet, Medical dictionary, NCA, Originality, HTTPS, SHTTP, European Economic Area, Headquarters, NASK, Three-body problem, Privacy, Match, Database, Data entry, European Economic Community, MSSO, Module, ZIP, Acknowledgment, Acronym, Environment, Message, MLM, Access, Conference, Pharmacovigilance, XML, EMA, Gateway, Chapter One, MedDRA, Active ingredient, Communication, Validation, Public, Data analysis, Precision, RTF, Navigation, Salt, Security, Chapter Five, Contextual, International organization, Convention, SME, URL, Chapter Four, ID, MAH, Rich Text Format, Microsoft Edge, EudraVigilance, Name, MSK, UNK, Risk, Create, Tree view, ICSR, Chapter Three, Web browser, Commercial, R2, Socs, TAB, Literature, Courier, CIOMS, EV, Built-in self-test, Documentation, Coreidae, Council, S-HTTP, File Explorer, UI, Import, Calendar, WEB, Reproduction, Jousting, PDF, Economic union, Mobile phone
Key Points: 

    Notice of Ericsson's Annual General Meeting 2024

    Retrieved on: 
    星期三, 二月 28, 2024
    Transfer, Person, Travel, Greenhouse, Nasdaq Stockholm, Annual report, F5, Inc., Cisco, Peer group, Corporation, Bank statement, Equity swap, IBM, Ethics, Participation, Compensation, Section 31, Swedish, Social Security, Treasury, Companies Act, Remuneration, Guideline, Chapter Four, Executive, Woman, Committee, Motorola Solutions, Calendar, ESG, LTV, Carbon, Business travel, Employment, Carbon accounting, GHG, Acquisition, KC, Air travel, Note, TSR, CGI Inc., Investor AB, AGM, Annual, Security (finance)

    Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.

    Key Points: 
    • Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.
    • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.
    • The Company has decided to implement one other share-related compensation program for 2024: the Key Contribution Plan 2024 ("KC Plan 2024").
    • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.

    Notice of Ericsson's Annual General Meeting 2024

    Retrieved on: 
    星期三, 二月 28, 2024
    Transfer, Person, Travel, Greenhouse, Nasdaq Stockholm, Annual report, F5, Inc., Cisco, Peer group, Corporation, Bank statement, Equity swap, IBM, Ethics, Participation, Compensation, Section 31, Swedish, Social Security, Treasury, Companies Act, Remuneration, Guideline, Chapter Four, Executive, Woman, Committee, Motorola Solutions, Calendar, ESG, LTV, Carbon, Business travel, Employment, Carbon accounting, GHG, Acquisition, KC, Air travel, Note, TSR, CGI Inc., Investor AB, AGM, Annual, Security (finance)

    Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.

    Key Points: 
    • Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.
    • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.
    • The Company has decided to implement one other share-related compensation program for 2024: the Key Contribution Plan 2024 ("KC Plan 2024").
    • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.

    Global Plastics in Electrical and Electronics Market Size, Share & Trends Analysis Report 2024-2030, by Polymer (ABS, PP), Application (Wires & Cables, Electrical Insulation), Region and Segment

    Retrieved on: 
    星期三, 二月 21, 2024
    Chapter Three, Electric Blue (TV series), USD, Medicine, Wire, Polychlorinated biphenyl, AI, Plastic, Computer, ABS, Internet of things, Electronics, Growth, Urbanization, Communication, PP, Safety, PVC, Meta Platforms, Amazon (company), Cloud computing, Estimation, Tablet, Microsoft, Chapter Four, Speciality chemicals

    DUBLIN, Feb. 21, 2024 /PRNewswire/ -- The "Global Plastics in Electrical and Electronics Market Size, Share & Trends Analysis Report by Polymer (ABS, PP), Application (Wires & Cables, Electrical Insulation), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

    Key Points: 
    • DUBLIN, Feb. 21, 2024 /PRNewswire/ -- The "Global Plastics in Electrical and Electronics Market Size, Share & Trends Analysis Report by Polymer (ABS, PP), Application (Wires & Cables, Electrical Insulation), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
    • Surging disposable income and increasing demand for energy efficiency are factors contributing to the growth of electrical & electronics market worldwide.
    • An expansion of electronics industry, driven by the emergence of 5G, IoT, and AI technologies, has driven the demand for plastics in electrical & electronics market.
    • Moreover, increasing demand from building & construction industry globally is anticipated to boost demand for plastics across electrical & electronics industry.